Trellus Health, a NYC-based digital health solution for chronic conditions, raised $5m in seed funding.
The round was led by Mount Sinai Health System (MSHS) and EKF Diagnostics.
The company has also entered into an exclusive multi-year contract with MSHS to commercialize its patent pending GRITT-IBDTM resilience assessment and personalized treatment methodology.
Co-founded by Marla Dubinsky, MD, and Laurie Keefer, PhD, and led by Monique Fayad, CEO, Trellus Health provides a digital health solution for chronic conditions, with an initial focus in Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis. Through its multidisciplinary connected care platform, the company coordinates expert whole-person care, including both clinical and behavioral health, to improve outcomes and to reduce healthcare costs for patients, employers, and the healthcare system. The company leverages its patent-pending GRITT-IBDTM resilience assessment and personalized treatment methodology, developed at the Mount Sinai Health System, to support patient resilience and wellness.